Stratagene, Rosetta to develop RNA purification system

By Elaine Rigoli

Tampa, Fla., Aug. 14 - Stratagene Corp. said it has entered into a joint development and license agreement with Rosetta Inpharmatics LLC to create an automated solution for the isolation of nucleic acids from a variety of clinical samples.

Under the agreement, Stratagene and Rosetta will jointly develop a proprietary instrument and a single-use consumable that will be manufactured and commercialized by Stratagene. These products will be sold to Stratagene's current customer base and companies engaged in pharmacogenomics. Financial terms of the agreement were not disclosed.

Nucleic acid purification allows researchers to separate RNA contained in biological samples. Clinicians and researchers can use the purified RNA to perform gene expression analysis and other functions within molecular diagnostics.

"This agreement with Rosetta Inpharmatics is a significant opportunity for Stratagene and marks another milestone in our molecular diagnostics strategy. We believe we have a unique opportunity to create and introduce a differentiated product that will automate the RNA purification process and provide consistent, reproducible results. These two characteristics are critical capabilities in gene expression analysis," Stratagene president and chief executive officer Joseph A. Sorge said in a news release.

Stratagene, based in La Jolla, Calif., develops specialized life science research and diagnostic products.

Based in Seattle, Rosetta is a wholly owned subsidiary of Merck & Co., Inc. and develops technologies to improve drug discovery.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.